Module 6
ICH Q7 and Active Pharmaceutical Ingredient GMP
Course Overview
This course provides the comprehensive operational understanding needed by professionals working in, supplying, contracting, auditing or regulating the manufacture of Active Pharmaceutical Ingredients. It addresses the distinct GMP framework that governs API manufacture under ICH Q7 and EU GMP Part II, and the practical realities of operating a GMP-compliant API facility or managing an API supplier relationship to that standard.
API manufacture sits at the foundation of every medicinal product. An API of inadequate quality cannot be rescued by downstream finished product manufacturing, no matter how well controlled the finished product steps are. The contamination risks, impurity profiles, residual solvents, genotoxic impurities and process-related substances introduced at the API stage carry forward into every batch of finished product made from that material. The regulatory framework reflects this reality: API GMP is not a relaxed version of finished product GMP, it is a distinct framework calibrated for the chemistry, scale, equipment and process characteristics of substance manufacture.
This course is designed for professionals operating within API manufacturing organisations and for finished product manufacturers who source API from third parties and carry the supplier oversight obligation that comes with that arrangement. It addresses what ICH Q7 requires, where API GMP differs from finished product GMP, how the starting material designation is established and defended, how impurity control and residual solvent management operate in practice, how API change control interfaces with finished product change control, and how QPs, RA professionals and audit teams should approach API supplier qualification with the seriousness the regulatory framework demands.
API manufacture is also an increasingly contested area of regulatory scrutiny. FDA Warning Letters and EU GMP non-compliance statements against API manufacturers, particularly those operating outside their territory of inspection origin, are a persistent feature of the regulatory landscape. Finished product manufacturers carry direct exposure when an API supplier fails. This course addresses both the manufacturing side and the supplier oversight side of that reality.
Learning Outcomes
By the end of this course, learners will be able to:
- Explain the regulatory basis for API GMP under ICH Q7 and EU GMP Part II, and describe how API GMP differs from finished product GMP in scope, expectations and operational application.
- Describe how the starting material designation is established, what regulatory evidence is required to defend it, and why the starting material decision affects the scope of GMP application across the synthetic route.
- Recognise how API process design, synthetic route selection, intermediate controls, isolation and purification steps, crystallisation, particle size control and drying affect API quality attributes and downstream finished product performance.
- Explain the principles of API impurity control, including process-related impurities, degradation products, residual solvents under ICH Q3C, elemental impurities under ICH Q3D and genotoxic impurities under ICH M7.
- Distinguish between API regulatory starting materials, intermediates, isolated intermediates, raw materials and starting materials of biological origin, and apply the appropriate GMP framework to
- Apply ICH Q7 expectations to API equipment qualification, cleaning validation, analytical method validation, process validation, change control, deviation management and CAPA in an API manufacturing context.
- Recognise the particular challenges of API GMP including campaign manufacture, multi-product facilities, dedicated facilities for highly hazardous APIs, custom synthesis arrangements and the supplier-customer interface for outsourced steps.
- Identify how API supplier qualification, audit, ongoing oversight and change notification arrangements should be structured to satisfy finished product manufacturer obligations.
- Recognise situations requiring escalation, including unauthorised API supplier changes, impurity profile shifts, residual solvent excursions, starting material designation challenges, audit findings affecting supply continuity and regulatory action against an approved API source.
- Apply ICH Q7 expectations within the local Pharmaceutical Quality System, whether operating as an API manufacturer or as a finished product manufacturer overseeing an API supply.
3.5Hrs of instructor led learning
Usable documents and templates
Real work examples and exercises
Course Content
API GMP has its own framework for good reason. The chemistry, scale, equipment and operational realities of substance manufacture are fundamentally different from those of finished product manufacture. Reactors, distillation columns, crystallisers, centrifuges, dryers and milling equipment operate on different principles to tablet presses, filling lines and lyophilisers. Process residues from solvent chemistry differ from residues from formulated product manufacture. The contamination control challenges of a multi-product synthesis facility differ from those of a multi-product finished product facility. Applying finished product GMP expectations to API manufacture would be both inappropriate and impractical, and applying API GMP expectations to finished product manufacture would leave material gaps in patient protection.
ICH Q7 was developed to provide a framework calibrated for these realities. Adopted into EU GMP as Part II and recognised by FDA, MHRA, PMDA and other major authorities, it sets the GMP expectations that apply to API manufacture from the starting material stage through to release of the API for use in finished product manufacture. It is not a guidance document; in the jurisdictions that have adopted it as binding GMP, it carries the same regulatory weight as finished product GMP requirements.
For finished product manufacturers, the API supplier relationship is a regulatory exposure that cannot be delegated away. The marketing authorisation holder is responsible for the quality of the API used in their product. Regulatory action against an API supplier becomes the finished product manufacturer’s problem when alternative sources are not qualified, when supply continuity is disrupted, or when impurity profile changes invalidate the registered finished product. The 2007-2008 heparin contamination crisis, the persistent nitrosamine impurity issues that have affected multiple finished product classes since 2018, and recurring impurity-driven recalls demonstrate that API supplier oversight is not a paperwork exercise. It is a patient safety function that the finished product manufacturer carries directly.
This course is essential because the API GMP framework is widely under-appreciated outside dedicated API manufacturing organisations. Finished product QA professionals often have limited exposure to the synthetic chemistry context that ICH Q7 addresses. Procurement and supplier quality functions may approve API suppliers without understanding the GMP expectations that supplier carries. Regulatory affairs teams may not appreciate how a starting material redesignation or an impurity profile change affects their registered product. And API manufacturers themselves vary widely in their familiarity with the regulatory expectations that apply to their operations, particularly those operating in jurisdictions with limited regulatory inspection history.
The regulatory framework for API GMP
The course opens by establishing the regulatory basis for API GMP under ICH Q7 and EU GMP Part II. Learners will understand how ICH Q7 was developed, how it was adopted across major regulatory regions, and how it sits within the wider GMP framework. The course explains the relationship between ICH Q7, finished product GMP, EU GMP Annex 18 (which incorporates ICH Q7) and the various national implementations.
Starting material designation
A dedicated section addresses the starting material designation, which is one of the most consequential decisions in any API manufacturing process. Learners will understand the regulatory expectations for starting material selection under ICH Q11, how the designation affects the scope of GMP application across the synthetic route, what evidence is required to justify the designation in a regulatory submission, and how starting material redesignation requests are evaluated by regulators. The course explains why starting material decisions sit at the centre of so many API regulatory queries and what the consequences are of poorly defended designations.
API process design and synthetic route
The course addresses the principles of API process design from a GMP perspective. This includes synthetic route selection considerations, the impact of route changes on impurity profiles, the role of intermediate isolation in controlling carry-over impurities, the use of in-process controls to manage critical process parameters, and the relationship between process design and the control strategy.
Impurity control: process-related impurities, residual solvents, elemental impurities and genotoxic impurities
A major section focuses on impurity control under ICH Q3A, Q3B, Q3C, Q3D and M7. Learners will understand how process-related impurities are identified, controlled and qualified, how residual solvents are categorised and limited under ICH Q3C, how elemental impurities are assessed and controlled under ICH Q3D, and how potentially genotoxic impurities are assessed under ICH M7 including the Threshold of Toxicological Concern approach. The course explains how impurity specifications are derived, defended and updated, and how supplier-driven impurity changes can affect registered finished products.
Equipment, facilities and process validation in API manufacture
The course covers the application of ICH Q7 to API equipment qualification, cleaning validation, analytical method validation and process validation. Particular attention is given to the differences between API and finished product equipment qualification practice, the principles of cleaning validation for solvent-based residues, the challenges of analytical method development and validation in complex synthetic mixtures, and the application of FDA three-stage process validation thinking to API processes.
Change control, deviation management and CAPA in an API context
API change control has particular features that distinguish it from finished product change control, including the regulatory commitments held in the API regulatory submission, the obligation to notify finished product customers, the impact of synthetic route changes on registered impurity profiles, and the cascading consequences of upstream changes on downstream processing. The course addresses these features in detail and explains how API deviations and CAPAs should be managed within the framework.
Campaign manufacture, multi-product facilities and dedicated facilities
The course addresses the operational realities of API facility design and use. This includes campaign manufacture and changeover cleaning, multi-product facilities and their cross-contamination control challenges, dedicated facilities for highly hazardous or highly potent APIs, and the regulatory expectations for facility classification and segregation based on the products manufactured.
API supplier oversight from a finished product manufacturer perspective
A dedicated section addresses API supplier qualification, ongoing oversight and audit from the finished product manufacturer perspective. Learners will understand what supplier qualification should establish, how API supplier audits should be designed and conducted, what change notification arrangements should be in place, how to respond to regulatory action against an approved API source, and how to build resilience into API supply through dual sourcing, strategic stockholding and qualified alternatives.
Inspection readiness for API manufacture
The final section addresses inspection readiness for API manufacturing operations. The course explains how FDA and EU GMP inspections of API facilities are conducted, what inspectors typically focus on, what common findings look like, and how to prepare an API site for inspection scrutiny across documentation, process control, impurity management, supplier oversight and quality system effectiveness.
- API manufacturing professionals at all levels, including production, QA, QC, validation, regulatory affairs and senior leadership within API manufacturing organisations.
- Finished product manufacturers’ supplier quality teams responsible for API supplier qualification, audit, ongoing oversight and change notification management.
- Qualified Persons and QA professionals responsible for batch certification decisions where API quality, supplier status or impurity profile change is a material consideration.
- Regulatory Affairs professionals managing API regulatory submissions, starting material designations, impurity specifications and post-approval changes affecting API supply.
- Technical operations, process development, MSAT and manufacturing science teams involved in API process design, route selection, scale-up and technology transfer.
- Procurement teams whose decisions about approved API suppliers and supply arrangements carry direct regulatory significance.
- QC analysts and laboratory managers responsible for API testing, impurity analysis, residual solvent determination and analytical method development in an API context.
- Internal auditors, supplier auditors and compliance professionals conducting audits of API manufacturing sites.
- CDMOs and CMOs offering API manufacturing services and the contract partners who manage those arrangements.
- Senior leaders and executive teams accountable for API supply continuity, supplier risk and the regulatory standing of API sources used in their licensed products.
You will gain a comprehensive understanding of the regulatory framework that governs API manufacture and the operational realities of running a GMP-compliant API operation or overseeing one. You will be able to interpret ICH Q7 with the precision the regulatory framework demands, recognise where API GMP diverges from finished product GMP and apply the right framework in the right context.
For those in API manufacturing roles, this course builds the regulatory authority needed to defend operational decisions to inspectors, customers and corporate leadership. For those in finished product manufacturing roles overseeing API supply, it builds the supplier oversight competence needed to protect your registered products from upstream failures.
Organisations benefit from a workforce that understands API GMP as the distinct framework it is, rather than treating it as a variant of finished product GMP. This strengthens API supplier qualification programmes, improves the quality of supplier audits, sharpens API change impact assessment, supports more credible regulatory submissions for API content and reduces the risk of supply chain disruption arising from inadequate supplier oversight.
For API manufacturers, the course supports stronger inspection readiness, more defensible regulatory submissions and improved customer confidence. For finished product manufacturers, it supports better protection of registered products from upstream impurity profile changes, supplier regulatory action and supply continuity disruption.
The cost of building genuine API supplier oversight is reliably lower than the cost of managing a major supplier failure. Organisations that have lived through nitrosamine impurity remediation, supplier consent decrees or sudden API supply withdrawal know this precisely.
- Comprehensive expert video content covering ICH Q7, EU GMP Part II, API process design, impurity control, validation, change management and supplier oversight.
- Real-world case studies from API manufacturing, finished product supplier oversight, regulatory action management and impurity-driven product recall environments.
- Practical examples of starting material designation, synthetic route selection, impurity profile management, residual solvent control and supplier audit conduct.
- Cross-functional scenarios showing how production, QC, QA, regulatory affairs, procurement and senior leadership affect API GMP compliance and supply continuity.
- Exercises on API supplier qualification, change notification assessment, impurity specification defence and audit finding response.
- Inspection-readiness scenarios focused on defending API manufacturing decisions and managing regulatory action against an approved API source.
- Multi-choice assessment
- Certificate of completion upon passing the
Course Details
Instructor(s):
Paul Palmer
Level:
Core Principles
Duration:
3.5 Hours
Type:
On Demand
Launch Yourself Into The Future.
Join Academy Pharmaceutical Excellence to gain industry-leading knowledge and skills through our comprehensive courses designed for aspiring professionals.